Jacobson Pharmaceuticals (02633.HK) announces a joyful increase in profits, with expected equity holders' share of profits for the fiscal year 2025 to increase by over 10% year-on-year.

The Jacobi Pharmaceutical Group (02633.HK) announced that it expects a year-on-year increase of over 40% in net profit from its continuing operations for the fiscal year ending March 31, 2025. This is mainly attributed to the strong performance of specialized drugs and overall non-patent drug businesses, as well as the revenue contributions from newly authorized products and strong launches of new products. Additionally, the improvement in operating leverage of production facilities and cost savings from effective cost control measures have also driven the growth.